Comparative Pharmacology
Head-to-head clinical analysis: CEFUROXIME SODIUM IN PLASTIC CONTAINER versus SUPRAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFUROXIME SODIUM IN PLASTIC CONTAINER versus SUPRAX.
CEFUROXIME SODIUM IN PLASTIC CONTAINER vs SUPRAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime is a beta-lactam cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has bactericidal activity against susceptible organisms.
Cefixime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
1.5 g IV every 8 hours for moderate to severe infections; may be increased to 3 g IV every 8 hours for severe or life-threatening infections.
400 mg orally once daily or 200 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 1.2-1.9 hours. Prolonged in renal impairment (up to 15-20 hours with CrCl <20 mL/min).
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 11-15 hours in severe renal impairment (CrCl <20 mL/min).
Renal excretion: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary/fecal: <10%.
Renal: 50-55% unchanged in urine; biliary/fecal: 10-20% (biliary excretion); remainder metabolized or excreted via feces.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic